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Abstract When new technical possibilities arise in health
care, often attunement is needed between different actors
from the perspectives of research, health care providers,
patients, ethics and policy. For cystic fibrosis (CF) such a
process of attunement in the Netherlands started in a
committee of the Health Council on neonatal screening
in 2005. In the balancing of pros and cons according to
Wilson and Jungner criteria, the advantages for the CF
patient were considered clear, even though CF remains a
severe health problem with treatment. Nevertheless,
screening was not started then, mainly since the specific-
ity of the tests available at that time was considered too
low. Many healthy infants would have been referred for
sweat testing and much uncertainty would arise in their
parents. Also the limited sensitivity for immigrants and
the detection of less severe phenotypes and carriers were
considered problematic. The Health Council recommen-
ded a pilot screening project which was subsequently
performed in some provinces, leading to a 4-step protocol:
IRT, PAP, screening for a CFTR mutation panel, and
sequencing of the CFTR gene. This would lead to the
identification of 23 cases of classical CF, two infants
with less severe forms and 12 carriers per year in the
Netherlands. Thus many CF patients can be diagnosed
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early, while limiting the number of referrals, the number
of infants with less severe forms diagnosed and the
number of carriers identified. Technical solutions were
found to limit the ethical problems. A nationwide program
using this four step protocol started by 1 May 2011.
Abbreviations
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane regulator
CHOPIN Cystic fibrosis heelprick screening in a
newborn population in the Netherlands
EGA Extended gene analysis
IRT Immunoreactive trypsinogen
PAP Pancreatitis associated protein
Introduction
Cystic fibrosis (CF), also known as mucoviscidosis, is an
autosomal recessive condition causing chronic obstructive
pulmonary disease, nutritional problems, pancreatic fibrosis,
hepatic fibrosis, diabetes and azoospermia. The life expec-
tancy of cystic fibrosis patients has increased in the last
decades: in 1960-1970 50% of patients in the Netherlands
reached the age of 8 years (Dankert-Roelse et al. 1986), in
1983 the average life expectancy was 23 years, and nowa-
days it is 35–40 years. Neonatal screening has long been
expected to contribute to a longer and healthier life in CF
patients. In 1978 a Dutch study reported on the results of a
pilot to detect albumin in meconium of 68,000 neonates
(Ten Kate 1978). The positive predictive value of the test
turned out to be only 3.39%, and thus it was concluded that
screening might have more disadvantages than not screen-
ing. In the same period several other countries did start CF
screening (Grosse et al. 2006). Australian colleagues started
detecting IRT in blood samples, and showed that hospital
admissions in the first two years of life were reduced in
screened patients (a mean of 3.9 days in the first two years
of life in screened vs. 27.3 days in unscreened patients)
(Wilcken and Chalmers 1985). An important question is
whether life expectancy is increased by screening. No such
increase was found in an early randomized controlled trial in
Wisconsin, since screened patients who met in the CF centre
unfortunately had earlier colonization with Pseudomonas
aeruginosa (Southern et al. 2009). This has influenced the
decision making in the Netherlands, even after later studies
showed better pulmonary outcomes, nutritional benefits and
reduced CF-related mortality risk to approximately 10 years
of age after CF neonatal screening (Grosse et al. 2006;
Southern et al. 2009).
This paper describes the process of decision making in
the Netherlands to advise against cystic fibrosis newborn
screening in 2005, the improvements of test properties
until it was considered appropriate to be included in the
program and nationwide screening was started by 1 May
2011.
Insufficient specificity?
High throughput techniques made neonatal screening for
many diseases technically possible after the year 2000.
New technical possibilities need attunement by all parties
involved, such as scientists in laboratories and clinics,
physicians and other professionals in (public) health care,
patients (organizations) and regulatory, advisory and
governmental agencies (Achterbergh et al. 2007).
In The Netherlands the Health Council installed a
commission to study the pros and cons of potential neona-
tal screening possibilities in 2005, from the point of view
of a diversity of backgrounds, including paediatrics, genet-
ics, ethics and law (Health Council of the Netherlands.
Neonatal Screening. The Hague: Health Council of the
Netherlands 2005). The report led to the extension of the
program to 17 disorders, not including cystic fibrosis. The
fact that cystic fibrosis treatment confers a substantial
health gain was considered beyond dispute. The question
was, however, how much screening immediately after birth
contributes to this health gain? The committee considered
cystic fibrosis a “borderline case”, as the evidence of health
gain was less compelling than in the case of disorders such
as phenylketonuria and hypothyroidism. The advantages of
neonatal screening for cystic fibrosis, namely a better nu-
tritional status, prevention of an often protracted and ag-
gravating diagnostic process and a decrease in the number
of incidents of sickness and hospital admissions were con-
sidered clear (Health Council of the Netherlands. Neonatal
Screening. The Hague: Health Council of the Netherlands
2005). The imperfections of the screening were however
the main reason not to advise to include cystic fibrosis in
the neonatal screening program, but rather to undertake
research into better screening methods. In the 2005
Health Council report (Health Council of the Netherlands.
Neonatal Screening. The Hague: Health Council of the
Netherlands 2005), an IRT/DNA screening program was
estimated to lead to the diagnosis of 50-60 patients per
year, 600 infants referred for sweat test, and 400 hetero-
zygotes diagnosed (carriers of CF). The Health Council
recommended to include cystic fibrosis in neonatal heel
prick screening as soon as a test method would become
available with a high specificity (as low specificity leads
to a great number of clinical investigation of unaffected
neonates). A study to improve the test properties of
cystic fibrosis neonatal screening was indeed initiated:
CHOPIN (Cystic fibrosis heelprick screening in a new-
born population in the Netherlands).
636 J Inherit Metab Dis (2012) 35:635–640
CHOPIN pilot study
A pilot study to improve test properties was performed in
2008 and 2009 in four provinces of the Netherlands:
Utrecht, Gelderland, Noord-Brabant and Limburg. The
study was led by two of us (JD and AV). Two screening
strategies were compared: measuring the serum concentra-
tion of immunoreactive trypsinogen (IRT) followed by pan-
creatitis associated protein (PAP) (Sarles et al. 2005) vs IRT
followed by a DNA test panel of 35 mutations in the cystic
fibrosis transmembrane regulator (CFTR) gene1 and, if one
CFTR mutation was found, extended gene analysis (EGA;
DNA sequencing of all coding exons and intron/exon
boundaries of the CFTR gene). In 2011 the results of the
study have been accepted for publication (Vernooij-van
Langen et al. 2011), but a short summary of the results
was already presented in a 2010 Health Council report (Health
Council of the Netherlands. Neonatal screening for cystic
fibrosis. The Hague: Health Council of the Netherlands
2010). Apart from the two strategies followed in the pilot, a
third scenario has been calculated, combining the two strate-
gies. IRT/PAP leads to a relatively large number of referrals
(119 as compared to 20 in the IRT/CFTRmutation panel/EGA
strategy). The specificity of IRT/CFTRmutation panel/EGA is
higher but this strategy will also identify carriers and less
severe forms of CF, as can be seen in Table 1. PAP as a second
step added to the IRT/CFTRmutation panel/EGA strategywill
reduce the number of carriers and less severe forms. Thus IRT/
PAP/CFTR mutation panel/EGA combines the best screening
test properties.
From pilot to national program
The Health Council again asked a committee to advise on CF
newborn screening after the CHOPIN study had been finished
(Health Council of the Netherlands. Neonatal screening for
cystic fibrosis. The Hague: Health Council of the Netherlands
2010). Apart from the strategies above, the committee dis-
cussed the IRT limit (≥50 μg/l0 the 2.43% highest concen-
trations vs. ≥60 μg/l0 the highest 1.03%), and considered that
an increase of the limit for IRT to 60 μg/l produces a sharp
drop in the number of non-classical CF patients identified by
the screening. Also, in case of IRT≥100 μg/l and PAP≥
1.6 μg/l, sequencing of the CFTR gene was included even if
none of the 35 mutations was present, since then the risk of a
rare mutation is relatively high. A four step protocol was
proposed for the national program (Fig. 1):
1. IRT <60 μg/l: negative, otherwise
2. PAP<3.0 μg/l if IRT 60–100 μg/l or < 1.6 μg/l if IRT
≥100 μg/l : negative, otherwise
3. CFTR mutation panel including all common CFTR
mutations in the Netherlands. Proceed to next step if 1
mutation or IRT≥100 μg/l and PAP≥1.6 μg/l :
4. DNA sequencing of all coding exons and intron/exon
boundaries of the CFTR gene
The PAP cut off levels are identical to the ones earlier
reported by Sarles et al. (2005). However, recently the
manufacturer of the PAP kits has recognized a systematic
error in his calibration procedure. This four step protocol
uses the corrected values (Dagorn 2011).
This protocol was expected to identify 25 CF patients
on an annual basis, additional to four infants already
diagnosed because of meconium ileus (Health Council of
1 Using the LiPA test (INNO-LiPA CFTR 19 en INNO-LiPA CFTR
17+Tn; Innogenetics, Gent, Belgium) the following CFTR muta-
tions can be detected: exon 2-3del (21 kb), 394delTT, E60X, G85E,
R117H, 621+1G>T, 711+1G>T, 711+5G>A, 1078delT, R334W,
R347P, A455E, I507del, F508del, 1717-1G>A, G542X, G551D,
Q552X, R553X, R560T, 1898+1G>A, 2143delT, 2183AA>G,
2184delA, 2789+5G>A, 3120+1G>A, 3199del6, 3272-26A>G,
3659delC, R1162X, 3849+10kbC>T, 3905insT, S1251N, W1282X
en N1303K. This test also identifies the CFTR polymorphism Tn in
intron 8 which is important in cases where the mutation R117H is
detected. Mutation I148T, which is still part of this test, was
ignored since this mutation is not considered disease-causing
anymore.
Table 1 Results heel prick screening (CHOPIN study) of 72 874 newborns (Health Council of the Netherlands. Neonatal screening for cystic
fibrosis. The Hague: Health Council of the Netherlands 2010)
IRT≥50 μg/l and PAP≥1.8 μg/l*
or IRT≥100 μg/l and PAP≥1.0 μg/l




Abnormal results 119 20 12
Classical CF 10 10 10
Non-classical CF 0 9 2
Carriers 0 89 5
* Up to 2010 Dynabio based its PAP-kit calibrators on the assumption that a 3 mm-punch contains 5 μl blood. The CDC Newborn Screening
Annual summary reports however show that this volume is in fact 3 μl. (Adam et al. 2000). Hence, Dynabio issued a statement in March 2011 via
the website of the International Society for Neonatal Screening (Dagorn 2011) that all concentrations should be corrected by multiplying them by a
factor of 5/3.
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the Netherlands. Neonatal screening for cystic fibrosis. The
Hague: Health Council of the Netherlands 2010). Only 12
carriers of CF would be identified. Out of the 25 CF patients
23 were expected to have only mutations from the panel and
two to be identified by extended mutation analysis. This
protocol was proposed by the Health Council for national
implementation, and accepted by the ministry of Health.
After the start of the four step protocol on a nationwide
basis by 1 May 2011, in the first 3 months 11 CF patients
were identified: eight because of two mutations in the panel
and three with one mutation in the panel and one identified
by sequencing the CFTR gene, as preliminary reported by
the laboratories involved.
Due to the screening program CF patients will have a
better nutritional status. An often protracted and aggravating
diagnostic process is prevented, a decrease in hospital
admissions anticipated and other benefits seem likely. The
specificity is >99.99%.
Sensitivity
While the specificity of CF neonatal screening was the main
test property to be improved, according to the Health Council
advice in 2005, also the sensitivity needed improvement. In
view of the large number of rare mutations not included in the
CFTR mutation panel a failsafe procedure was built in the
protocol. Earlier a failsafe procedure was performed in
Massachusetts using a multiple CF mutation screen, which
added somewhat to the sensitivity, however at the cost of
increased referrals and carrier identification (Comeau et al.
2004). In the current Netherlands procedure, theCFTR gene is
sequenced in the last step. The procedure is especially impor-
tant for infants with migrant ancestors, since the sensitivity of
the CFTR mutation panel was only 44% for Turkish migrants
and 69% for North African migrants in Europe (Health
Council of the Netherlands. Neonatal screening for cystic
fibrosis. The Hague: Health Council of the Netherlands
2010; Lakeman et al. 2008). TheCF carrier frequency in Dutch
inhabitants of Turkish and North African ancestry can only be
roughly approximated, but is estimated to be around 1 in 50.
The annual number of neonates with CF in these population
groups is estimated to be 1-2. The failsafe procedure consisted
of sequencing the CFTR gene in case of an IRT concentration
of ≥100 μg/l and PAP≥1,6 μg/l, also if no mutation was
identified using theCFTRmutation panel. It is hard to estimate
the sensitivity, but this is not expected to be 100%, due to IRT
and PAP. The consequence of pursuing an extremely high
specificity is in general a less optimal sensitivity. Based on
the CHOPIN study the sensitivity might be ±95%.
Is carrier status information an additional benefit?
While the goal of neonatal screening is to identify infants
with two CFTR mutations, that lead to the classical form of
Fig. 1 Four step screening
protocol Netherlands CF
screening programme 2011
Fig. 2 Punnett squares for an autosomal recessive disorder and for
parents of a CF carrier infant. Left: Punnett square for autosomal
recessive disorder. Right: Punnett square for parents of CF carrier
infant (large circle), one of which carries a CF allele (small circle). If
both parents do not have the CF phenotype, this carrier parent must
also have a normal CFTR allele (A). The risk for the unknown allele to
carry a CFTR mutation is the allele frequency of a. The risk to have a
child with CF is the ¼ x allele frequency
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cystic fibrosis, some infants will be diagnosed as CF car-
riers, having only one CFTR mutation. If the newborn child
is a carrier, then it follows that one, or both, parents (and
possibly other children) are carriers (Health Council of the
Netherlands. Neonatal screening for cystic fibrosis. The
Hague: Health Council of the Netherlands 2010). As this
may be relevant information to the parents in connection
with future family planning, they are informed of this sec-
ondary finding. Parents in this situation can be referred for
genetic counselling. At the moment the heel prick is per-
formed, parents can opt-out of receiving carrier status infor-
mation. To allow parents to make an informed decision on
(not) receiving carrier status information, the parents
should be alerted to these possible outcomes prior to
screening. Thus the information and counselling given
to parents during pregnancy becomes more complex.
After birth, information of this kind can, in practice, give
rise to misunderstandings with regard to the health of the
carriers.
In theory, genetic screening can be performed in different
phases of life: before conception, during pregnancy, in the
newborn or later in life. Before pregnancy (in preconcep-
tional screening) more reproductive options exist, such as
choosing not to have children (or adopting a child), preim-
plantation genetic diagnosis (embryo selection), prenatal
diagnosis and termination of affected foetuses, choosing a
different partner or using donor gametes (e.g. artificial in-
semination by donor sperm). However, in most countries
preconceptional screening for cystic fibrosis is not available
in health care.
Increase of CF risk
The Punnett squares in Fig. 2 show the information that can
be derived from the fact that a child of healthy parents is a
CF carrier. If the child is a carrier, at least one parent is
carrier as well. If none of the parents have the CF pheno-
type, the carrier parent must also have a normal CFTR gene.
If the carrier frequency in a population is 1:30, the allele
frequency is 1:60, and for each next pregnancy the risk of a
CF affected infant is 1/4x1/6001/240, much higher than the
birth prevalence would be (1/3600). A CF carrier test in the
parents might provide certainty. However, as the 2005
Health Council report (Health Council of the Netherlands.
Neonatal Screening. The Hague: Health Council of the
Netherlands 2005) mentions, “… it is not always possible
to determine for certain whether only one parent is a carrier
(as is the case with, for example, cystic fibrosis, where not
all mutations are known).” This holds true when CF testing
is based on a CFTR mutation panel. Sequencing of the
CFTR genes of the parents will reduce the residual risk to
a figure far lower than the population risk.
Future research
After the decision to start a national CF screening program,
there are several questions that remain to be answered.
Further evaluation of the sensitivity and the specificity
achieved in the current four steps is needed. In an a different
IRT/PAP study published last year the IRT/PAP strategy
according to Sarles et al. (2005) showed some limitations,
since not all CF patients with severe forms were found: PAP
values of 3 out of 13 newborns with CF (23%) were equal to
or below the cut-off level (Sommerburg et al. 2010). Further
evaluation might lead to changes of the cut-off levels.
Conclusion
The national neonatal CF screening program in the
Netherlands that is in place since 1 May 2011, has a
specificity >99.99%. The sensitivity is expected to be ±95%,
but further evaluation is needed. Carrier status information
is provided to only a small number, if parents do not opt
out. A clinical geneticist can provide counselling to carriers
upon request.
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